Broadfin Capital’s Lipocine LPCN Stock Holding History

Broadfin Capital’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-15,561	Closed	-$1.61M	–	75
2014 Q2	$1.61M	Buy	+15,561	New	+$1.86M	0.16%	66

Other funds holding LPCN

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

Del Mar Asset Management New York $76.5M AUM 20.86% 1-Year Est. Return

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital's LPCN Position: Q3 2014 in Review

Broadfin Capital sold out of Lipocine (LPCN) in Q3 2014, closing a stake of 15,561 shares — an estimated $1.61M sold.

Broadfin Capital first reported a position in LPCN in Q2 2014 and held it in 1 quarter. The position peaked at $1.61M in Q2 2014. 17 funds tracked by Wall St. Rank hold LPCN as of Q3 2014.

Broadfin Capital reported no remaining Lipocine position as of Q3 2014 after selling out during the quarter.
Broadfin Capital sold 15,561 Lipocine shares in Q3 2014, an estimated $1.61M.
Broadfin Capital first reported a position in Lipocine in Q2 2014 and held it in 1 quarter.
Broadfin Capital's Lipocine position peaked at $1.61M in Q2 2014.
17 funds tracked by Wall St. Rank held Lipocine as of Q3 2014.

Based on Broadfin Capital's 13F filing for Q3 2014, filed 14 Nov 2014.